Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.

Expert opinion on biological therapy - 1 Jan 2012

Ghazi Aasia, Trikha Anita, Calhoun William J

Abstract excerpt

INTRODUCTION: Benralizumab is a monoclonal antibody that binds the α subunit of the receptor to IL-5. As IL-5 is implicated in disease states that are mediated by eosinophils, benralizumab is an attractive option for use in the management of asthma. As a result of enhanced antibody-directed cell cytotoxicity, it has enhanced eosinophil-depleting activity as compared with neutralizing monoclonal antibody directed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Neutralizing

Share to Asthma

Share to Clinical Trials as Topic

Share to Eosinophils

Share to Immunotherapy

Share to Interleukin-5

Source

Open in PubMed Open full text

Identifiers

PMID: 22136436
DOI: 10.1517/14712598.2012.642359
PMCID: PMC3587289

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.PMID 22136436Read ↗

Benralizumab: The Immuno-Pharmacological State of the ArtSemantic proximity Read ↗

Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.Semantic proximity Read ↗

Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.Semantic proximity Read ↗

Treatment of Chronic Spontaneous Urticaria With Benralizumab: Report of Primary Endpoint Completer Analysis, Secondary and Exploratory EndpointsSemantic proximity Read ↗

Anti-interleukin-5 therapy in severe asthma.Semantic proximity Read ↗

An early Indian experience with benralizumab - A compendium on severe asthma cases: a case seriesSemantic proximity Read ↗

Anti-CD19/CD20 bispecific antibody with dual Fc domains mediates enhanced effector functions and durable depletion of memory B cells in vivoSemantic proximity Read ↗

Eosinophil Counts in Adults with Asthma Treated with Anti-IL-4Rα Rademikibart in a Randomized TrialSemantic proximity Read ↗

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.Semantic proximity Read ↗

Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthmaSemantic proximity Read ↗

An Engineered Human-Antibody Fragment with Fentanyl Pan-Specificity that Reverses Carfentanil-Induced Respiratory DepressionSemantic proximity Read ↗

Development of an inhibiting antibody against equine interleukin 5 to treat insect bite hypersensitivity of horsesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.